glp 1 powerpoint presentation GLP-1 and Diabetes Mellitus Semaglutide Advances In GLP 1

Consensus recommendations from the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) and American Association of Clinical Endocrinologists/American College of Endocrinology advocate that GLP-1 receptor agonists, among other therapies, should be considered as a second-line treatment option in people with type 2 diabetes when glucose levels are not well controlled on metformin (46)

Are GLP-1s and GIPs only used for people with diabetes, or can they support metabolic health in other individuals as well

Thus, the correlation between GLP-1RAs and tumors has also become a focus of attention in recent years

Expert Review of Clinical Pharmacology

The heightened occurrences of nausea and vomiting incidents found in the Wegovy trial align with the theory that semaglutide causes an increased risk of gastroparesis, since Wegovy is more than double the dose at 2.4mg compared to Ozempics 1mg dose

Compounded GLP-1 medications are prepared under 503A pharmacy standards